You are currently viewing a new version of our website. To view the old version click .

Recent Advances in Antitubercular Drug Discovery

This special issue belongs to the section “Medicinal Chemistry“.

Special Issue Information

Dear Colleagues,

Tuberculosis (TB) is still the leading cause of death from a single infectious disease agent, with an estimated 1.7 billion people infected with Mycobacterium tuberculosis, and more than 10 million new cases each year. The current anti-TB therapy has reduced the mortality, but it requires a long treatment period, and can have serious adverse reactions. Moreover, multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis strains have now spread worldwide and become a global issue. For these reasons novel TB drugs and novel drug targets are needed; indeed, considerable efforts, involving different approaches and expertise, have been made in the last years.

The aim of this Special Issue is, therefore, to collect research papers, short communications, and critical review articles, that are focused on the discovery and development of novel antitubercular drugs, new potential biological targets, and therapeutic approaches.

Dr. Laurent Chiarelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Tuberculosis
  • M. tuberculosis
  • Resistance mechanisms
  • Small molecules
  • Natural products
  • Drug design
  • Computational tools
  • Structure–activity relationships

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Published Papers

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Molecules - ISSN 1420-3049